Bispecific Antibodies: 3 Classes Reshaping Oncology

You’ve seen bispecific antibodies in the headlines: Tecvayli, Talvey, ivonescimab. You know they matter. But what do they actually do, and how do you size up a bispecific catalyst as an investor? Here is what matters as this drug class dominates oncology pipelines.

The Problem

A monoclonal antibody hits one target. A bispecific antibody hits two, simultaneously. That sounds like an incremental improvement. In oncology, it is not.

Bispecifics close the gap between traditional antibody drugs and cell therapies like CAR-T. They can physically tether a T-cell to a cancer cell and force the kill. They can block two immune-evasion pathways at once. And in multiple myeloma, they are matching CAR-T on efficacy while beating it on convenience. If you invest in oncology biotech and do not understand bispecifics, you are flying blind on some of the biggest catalysts in the 2026-2027 pipeline.

The Solution

Think of a bispecific antibody as a two-armed molecule: “Left arm grabs the cancer cell. Right arm grabs the T-cell. The T-cell kills the cancer cell.” That is the T-cell engager model. The other two major classes grab two cancer-driving receptors, or block two immune checkpoints at once. Each class has different investing dynamics.

Three Classes of Bispecific Antibodies

Class 1: T-Cell Engagers (BiTEs)

BiTE stands for Bispecific T-cell Engager. One arm binds a protein on the cancer cell (like BCMA on myeloma cells, or CD20 on B-cell lymphoma). The other arm binds CD3 on T-cells. By physically linking the two, the BiTE forces the T-cell to kill the cancer cell, regardless of whether the T-cell would have recognized the cancer on its own.

Real examples: Blincyto (blinatumomab), approved in 2014 for acute lymphoblastic leukemia, was the first BiTE. Modern versions have longer half-lives and better dosing schedules: Tecvayli (teclistamab) targets BCMA×CD3 for multiple myeloma, Talvey (talquetamab) targets GPRC5D×CD3, Columvi (glofitamab) targets CD20×CD3 for diffuse large B-cell lymphoma, and Imdelltra (tarlatamab) targets DLL3×CD3 for small cell lung cancer.

Investing implication: BiTEs cause cytokine release syndrome (CRS), a flood of immune signaling proteins that can cause fever, low blood pressure, and organ stress. CRS is similar to CAR-T but usually milder and resolves faster. The trade-off: BiTEs are off-the-shelf (no manufacturing wait, no weeks-long vein-to-vein process), but they require repeated dosing, not one-and-done. For an investor, the question is whether convenience beats curative potential. In July 2026, J&J reported that the Tecvayli + Talvey combination cut progression risk by 89% in heavily pretreated myeloma (MonumenTAL-6 trial). That is CAR-T-level efficacy without CAR-T logistics.

Class 2: Dual Checkpoint and Dual Pathway Inhibitors

These bispecifics block two immune-evasion pathways or tumor-growth signals simultaneously, combining what would otherwise require two separate drugs.

Real examples: Ivonescimab (PD-1×VEGF), developed by Akeso and licensed to Summit Therapeutics, blocks the PD-1 immune checkpoint and the VEGF angiogenesis pathway in one molecule. At ASCO 2026, ivonescimab plus chemo reduced the risk of death by 34% versus a PD-1 inhibitor plus chemo in first-line squamous non-small cell lung cancer (Harmoni-6 trial). Summit is running 16 Phase 3 trials. Pfizer has its own PD-1×VEGF bispecific (PF-08634404) in multiple Phase 3 registrational trials. Cadonilimab (PD-1×CTLA-4) and pumitamig (PD-L1×VEGF-A) are other clinical-stage examples.

Investing implication: The “two-target advantage” needs to justify itself. A bispecific that blocks PD-1 and VEGF should beat a PD-1 inhibitor alone. But does it beat PD-1 plus a separate VEGF drug? If the bispecific’s only advantage is combining two injections into one, the addressable market is smaller than the hype suggests. The ivonescimab thesis is that simultaneous binding creates an effect beyond what sequential drugs can achieve. Whether that is true is what the Phase 3 program will answer.

Class 3: Dual Tumor-Targeting

These bispecifics grab two different cancer-driving receptors on the same tumor cell. Zanidatamab (Ziihera) is a biparatopic antibody: it hits HER2 at two different binding sites, not two different targets. Amivantamab (Rybrevant) targets EGFR and MET, both drivers of non-small cell lung cancer. Zenocutuzumab (Bizengri) hits HER2 and HER3 for NRG1 fusion-positive solid tumors.

Investing implication: These are closer to traditional targeted therapies. The mechanism is easier to understand, the competition is easier to map, and the trial endpoints are standard (progression-free survival, overall survival). Jazz acquired zanidatamab through a $10.6B buyout, signaling pharma’s conviction that dual targeting adds enough value to justify the premium.

How to Evaluate a Bispecific Catalyst

Step 1: Know Which Class You Are Looking At

BiTE? Dual checkpoint? Dual tumor-targeting? The risk profile is different. BiTEs carry CRS risk and dosing complexity. Dual checkpoint bispecifics carry the burden of proving an additive benefit. Dual tumor-targeting bispecifics carry the classic targeted-therapy risks: resistance mutations, competitor overlap.

Step 2: Check ClinicalTrials.gov for the Primary Endpoint

Same framework as any oncology drug. The primary endpoint is locked in at trial registration. If the company changes it mid-trial, the revision history is public. Read the FDA label guide to understand how approved indications translate to addressable markets: /news/how-to-read-clinical-trial-press-release.

Step 3: Ask the Two-Target Question

Is the second target adding real clinical value, or just complexity? A bispecific that blocks PD-1 and CTLA-4 can produce more immune-related side effects without meaningfully better efficacy. Look for randomized data comparing the bispecific to each of its components, not just to placebo.

Step 4: Compare to CAR-T

For hematology bispecifics (myeloma, lymphoma): is the bispecific competing with CAR-T, or complementing it? Tecvayli + Talvey posts CAR-T-level efficacy. But CAR-T is one-and-done. Which matters more to patients and payers? That answer determines market share.

Common Mistakes

Assuming all bispecifics are the same. A BiTE and a dual checkpoint bispecific are as different as a screwdriver and a wrench. Evaluate the mechanism, not the label.

Ignoring CRS and manufacturing risk. BiTEs require step-up dosing and hospitalization for initial doses. This is a commercial headwind that does not show up in efficacy tables.

Buying on Phase 1 data. Bispecific enthusiasm runs high. Phase 1 single-arm data gets breathless coverage. Remember: roughly two-thirds of Phase 2 successes fail to replicate in Phase 3. A strong Phase 1 readout is a reason to watch, not a reason to buy.

Assuming ivonescimab replaces Keytruda. The Harmoni-6 data is China-only. The ongoing global Phase 3 (HARMONi-3) will determine the real market. China-only data in oncology has a mixed track record of replicating globally. See the oncology catalysts calendar for more context: /news/oncology-biotech-2026-catalysts.

Final Checklist

• Class identified: BiTE, dual checkpoint, or dual tumor-targeting?
• Primary endpoint checked on ClinicalTrials.gov. Is it randomized Phase 3 or single-arm Phase 1/2?
• Two-target advantage assessed: combination effect or redundancy?
• Competition mapped: CAR-T overlap? Other bispecifics targeting same combo?
• CRS profile and dosing schedule reviewed (BiTEs only)
• Read the latest data yourself. Do not rely on the press release headline

Bispecifics are not a monolith. They are three distinct drug classes under one name, and they are reshaping oncology faster than any modality since checkpoint inhibitors hit the market a decade ago. Learn the difference before you size up the next Tecvayli headline.

Sources: FDA-Approved Bispecific Antibodies: Complete List; Bispecific antibodies in oncology — a review (PMC)